Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 11, 2026
Irhythm Holdings, Inc. (IRTC)
A forensic read on Irhythm Holdings, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Safe
Financial health
5.6
Distress distance
Clean
Earnings quality
4
Forensic signals
-297.8
P / E (ttm)
-29.2%
ROE
$4.1B
Market cap
0.00%
Dividend yield
26.2%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Irhythm Holdings, Inc. earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 5.6, placing it in the Safe zone. 4 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-7.2%
FY2025
Return on invested capital.Return on invested capital is -7.2% in the latest fiscal year and rising from -32% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
+2.3%/yr
FY2022–FY2025
Share-count dilution.Diluted share count changed +7% over the last 3 years to FY2025 (+2.3%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~2.3% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~7%.
12% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 12% of revenue and 256% of free cash flow in FY2025 — about $2.76 per diluted share. The cost of it is not in the cash flow — no cash left the business — it is in the count: holders gave up about 2.3% of the company a year, and that rate is not falling. That is the figure to weigh, not the share of free cash flow.
stopped
FY2024→FY2025
Shareholder returns — halted.Capital returns have STOPPED — $25M of buybacks + dividends in FY2024, but ~$0 in FY2025. A halt usually means the company is conserving cash.
Key fundamentals
Latest Revenue$747.1M
Revenue Growth YoY+26.2%
Revenue CAGR (3yr)+22.0%
Net Margin-6.0%
Free Cash Flow$34.5M
Return on Equity-29.2%
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Irhythm Holdings, Inc.'s actual 10-K/10-Q/8-K filings?